Mike Cusnir, MD
Hematology & Oncology · Miami Beach, FLNPI 1962490631
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Sirtex Medical Inc at 45.9% of the total. Reporting peaked in 2022 at $35,125 and has fallen 52.2% since, to $16,779 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,388 payments — averaging $75.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$83K
- Ipsen Biopharmaceuticals, Inc$12K
- Eisai Inc.$8K
- Seagen Inc.$8K
- AstraZeneca$8K
- Jazz Pharmaceuticals Inc.$6K
- plus $55K from 54 others
Across 540 payments — averaging $3346.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$764K
- Mirati Therapeutics, Inc.$175K
- Exelixis Inc.$110K
- Otsuka Pharmaceutical Co., Ltd.$96K
- Incyte Corporation$94K
- Taiho Oncology, Inc.$93K
- plus $476K from 18 others
What the payments were for
- Consulting fees$41,02123%
- Speaking & faculty fees$88,08849%
- Travel & lodging$6,1923%
- Food & beverage$44,44625%
- Education$1,6091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,355 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 72 | $1,226,691 |
| XtandiEnzalutamide | 83 | $1,119,802 |
| ErleadaApalutamide | 54 | $776,664 |
| LenvimaLenvatinib Mesylate | 26 | $570,630 |
| Lenalidomide | 40 | $540,847 |
| LynparzaOlaparib | 35 | $490,222 |
| TagrissoOsimertinib Mesylate | 24 | $386,609 |
| TalzennaTalazoparib Tosylate | 22 | $337,695 |
| IbrancePalbociclib | 19 | $335,418 |
| JakafiRuxolitinib Phosphate | 13 | $260,359 |
| KisqaliRibociclib Succinate | 25 | $237,070 |
| CalquenceAcalabrutinib Maleate | 12 | $196,393 |
| VerzenioAbemaciclib | 11 | $170,319 |
| CreonLipase/Protease/Amylase | 41 | $102,952 |
| Abiraterone Acetate | 100 | $101,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $4,699 | $1,226,69172 claims |
| Astellas Pharma US IncXtandi | $1,774 | $1,119,80283 claims |
| AstraZenecaLynparza, Tagrisso, Calquence | $7,604 | $1,073,22471 claims |
| Johnson & JohnsonErleada | $3,255 | $776,66454 claims |
| PfizerTalzenna, Ibrance, Eliquis | $2,529 | $721,10296 claims |
| Eisai Inc.Lenvima | $7,926 | $570,63026 claims |
| Incyte CorporationJakafi | $1,590 | $260,35913 claims |
| NovartisKisqali | $4,597 | $237,07025 claims |
| Lilly USA, LLCVerzenio | $3,972 | $170,31911 claims |
| AbbVieCreon | $747 | $102,95241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami Beach
- Simon BlancMiami Beach$160K
- Jacqueline BarrientosMiami Beach$148K
- Bruno BastosMiami Beach$106K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.